| Literature DB >> 35514782 |
Hideki Shima1, Toshitaka Nakaya1, Ichizo Tsujino1,2, Junichi Nakamura1, Ayako Sugimoto1, Takahiro Sato1,2, Taku Watanabe1, Hiroshi Ohira1, Masaru Suzuki1, Masaru Kato3, Isao Yokota4, Satoshi Konno1.
Abstract
Right ventricular (RV) function critically affects the outcomes of patients with pulmonary hypertension (PH). Pressure wave analysis using Swan‒Ganz catheterization (SG-cath) allows for the calculation of indices of RV function. However, the accuracy of these indices has not been validated. In the present study, we calculated indices of systolic and diastolic RV functions using SG-cath-derived pressure recordings in patients with suspected or confirmed PH. We analyzed and validated the accuracies of three RV indices having proven prognostic values, that is, end-systolic elastance (Ees)/arterial elastance (Ea), β (stiffness constant), and end-diastolic elastance (Eed), using high-fidelity micromanometry-derived data as reference. We analyzed 73 participants who underwent SG-cath for the diagnosis or evaluation of PH. In this study, Ees/Ea was calculated via the single-beat pressure method using [1.65 × (mean pulmonary arterial pressure) - 7.79] as end-systolic pressure. SG-cath-derived Ees/Ea, β, and Eed were 0.89 ± 0.69 (mean ± standard deviation), 0.027 ± 0.002, and 0.16 ± 0.02 mmHg/ml, respectively. The mean differences (limits of agreement) between SG-cath and micromanometry-derived data were 0.13 (0.99, -0.72), 0.002 (0.020, -0.013), and 0.04 (0.20, -0.12) for Ees/Ea, β, and Eed, respectively. The intraclass correlation coefficients of the indices derived from the two catheterizations were 0.76, 0.71, and 0.57 for Ees/Ea, β, and Eed, respectively. In patients with confirmed or suspected PH, SG-cath-derived RV indices, especially Ees/Ea and β, exhibited a good correlation with micromanometry-derived reference values.Entities:
Keywords: Swan‒Ganz catheterization; high‐fidelity micromanometry; pulmonary hypertension; right ventricular function
Year: 2022 PMID: 35514782 PMCID: PMC9063972 DOI: 10.1002/pul2.12078
Source DB: PubMed Journal: Pulm Circ ISSN: 2045-8932 Impact factor: 2.886
Characteristics of the study population
| Total subjects ( | Pulmonary hypertension ( | Controls ( | |
|---|---|---|---|
| Age (years) | 58 ± 16 | 56 ± 17 | 62 ± 10 |
| Sex (female/male) | 49/24 | 35/22 | 14/2 |
| Body mass index (kg/m2) | 23 ± 5 | 23 ± 5 | 22 ± 6 |
| Pulmonary hypertension group (1/2/3/4/5) | 33/0/11/12/1 | NA | |
| WHO functional class (I/II/III/IV) | 12/15/28/2 | NA | |
| Use of pulmonary vasodilator(s) | NA | ||
| None | 17 | ||
| Single drug | 10 | ||
| Double combination | 18 | ||
| Triple combination | 12 |
Abbreviations: NA, not applicable; WHO, World Health Organization.
Results of Swan‒Ganz catheterization and cardiac magnetic resonance imaging
|
| |||
|---|---|---|---|
| Total subjects | Pulmonary hypertension | Controls | |
|
| 73 | 57 | 16 |
| PAWP (mmHg) | 7.6 ± 2.7 | 8.0 ± 2.7 | 6.3 ± 2.4 |
| MPAP (mmHg) | 28.9 ± 11.2 | 32.5 ± 10.0 | 16.1 ± 3.9 |
| RVEDP (mmHg) | 7.1 ± 3.0 | 7.9 ± 2.7 | 4.4 ± 2.6 |
| RAP (mmHg) | 3.8 ± 2.4 | 4.2 ± 2.4 | 2.3 ± 2.0 |
| CO (L/min) | 4.5 ± 1.0 | 4.5 ± 1.1 | 4.5 ± 1.0 |
| CI (L/min/m2) | 2.8 ± 0.6 | 2.8 ± 0.6 | 2.9 ± 0.5 |
| PVR (Wood unit) | 5.2 ± 3.5 | 6.0 ± 3.6 | 2.2 ± 0.9 |
Note: Data are presented as mean ± standard deviation (SD).
Abbreviations: CI, cardiac index; CO, cardiac output; Ees/Ea (Vol), Ees/Ea calculated with the volume method ([RV stroke volume]/[RV end‐systolic volume]); MPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RV, right ventricular; RVEDP, RV end‐diastolic pressure.
p < 0.05 versus Controls by Wilcoxon's test.
Figure 1Representative image of right ventricular pressure recorded via Swan–Ganz catheterization and high‐fidelity micromanometry. SG‐cath‐derived RVP showed fluctuations or notches near end‐diastole and after the steep increase in the systolic phase (arrows) (a), whereas Pressure‐cath‐derived RVPs showed no or slight fluctuations/notches (b). In addition, SG‐cath‐derived RVP and calculated indices of RV function, including Ees (MPAP), Ees (MPAPcalc), Ees/Ea (MPAP), Ees/Ea (MPAPcalc), β, and Eed, were higher than those obtained by Pressure‐cath. dp/dt‐max, maximum dp/dt; dp/dt‐min, minimum dp/dt; Ea, arterial elastance; Eed, end‐diastolic elastance; Ees, end‐systolic elastance; MPAP, mean pulmonary arterial pressure; MPAPcalc, calculated end‐systolic pressure using MPAP; Piso, isovolumic pressure; Pressure‐cath, high‐fidelity micromanometry; RVEDP, right ventricular end‐diastolic pressure; RVP, right ventricular pressure; SG‐cath, Swan–Ganz catheterization; SRVP, systolic right ventricular pressure
Comparison of right ventricular pressure and indices of right ventricular function evaluated with Swan‒Ganz catheterization and high‐fidelity micromanometry
| Swan‒Ganz catheterization | High‐fidelity micromanometry | Bland–Altman plot, mean difference (limits of agreement) | Intraclass correlation coefficient | |
|---|---|---|---|---|
|
| ||||
| HR (/min) | 69.8 ± 1.4 | 71.1 ± 1.4 | −1.3 (7.7, −10.3) | 0.92 |
| SRVP (mmHg) | 47.5 ± 2.1 | 43.0 ± 2.0 | 4.5 (11.3, −2.2) | 0.95 |
| RVP‐min (mmHg) | 2.3 ± 0.3 | 0.8 ± 0.3 | 1.5 (5.8, −2.8) | 0.62 |
| RVEDP (mmHg) | 6.6 ± 0.4 | 4.4 ± 0.3 | 2.2 (7.2, −2.9) | 0.49 |
| Piso (mmHg) | 67.9 ± 2.9 | 62.0 ± 2.1 | 6.0 (32.9, −21.0) | 0.77 |
| Ees/Ea (MPAP) | 1.46 ± 0.08 | 1.28 ± 0.06 | 0.18 (1.20, −0.84) | 0.60 |
| Ees/Ea (MPAPcalc) | 0.89 ± 0.69 | 0.76 ± 0.61 | 0.13 (0.99, −0.72) | 0.76 |
| Ees/Ea (SRVP) | 0.48 ± 0.04 | 0.53 ± 0.04 | −0.05 (0.53, −0.62) | 0.65 |
| dp/dt‐max (mmHg/s) | 502.6 ± 20.6 | 427.1 ± 13.7 | 75.5 (325.4, −174.4) | 0.57 |
| dp/dt‐min (mmHg/s) | −467.5 ± 18.4 | −445.4 ± 18.0 | −22.1 (119.2, −163.3) | 0.89 |
| Tau (s) (Weiss) | 43.5 ± 2.4 | 44.0 ± 2.0 | −0.5 (25.0, −26.1) | 0.76 |
| Tau (s) (Logistic) | 27.8 ± 1.5 | 35.5 ± 1.7 | −7.7 (24.8, −40.2) | 0.22 |
|
| ||||
| Ees (MPAP) (mmHg/ml) | 0.78 ± 0.06 | 0.63 ± 0.04 | 0.14 (0.74, −0.46) | 0.63 |
| Ees (MPAPcalc) (mmHg/ml) | 0.55 ± 0.37 | 0.41 ± 0.30 | 0.14 (0.74, −0.46) | 0.54 |
| Ees (SRVP) (mmHg/ml) | 0.34 ± 0.04 | 0.39 ± 0.05 | 0.06 (0.59, −0.48) | 0.65 |
|
| 0.027 ± 0.002 | 0.024 ± 0.001 | 0.002 (0.02, −0.013) | 0.71 |
| Eed (mmHg/ml) | 0.16 ± 0.02 | 0.12 ± 0.01 | 0.04 (0.2, −0.12) | 0.57 |
Note: Data are shown as mean ± standard error (SE).
Abbreviations: CMRI, cardiac magnetic resonance imaging; dp/dt‐max, maximum dp/dt; dp/dt‐min, minimum dp/dt; Ea, arterial elastance; Eed, end‐diastolic elastance; Ees, end‐systolic elastance; HR, heart rate; MPAP, mean pulmonary arterial pressure; MPAPcalc, calculated end‐systolic pressure using MPAP; Piso, isovolumic pressure; RVEDP, right ventricular end‐diastolic pressure; RVEDV, right ventricular end‐diastolic volume; RVP‐min, minimum right ventricular pressure; RVSV, right ventricular stroke volume; RVV, right ventricular volume; SRVP, systolic right ventricular pressure.
Calculated using the single‐beat method.
Calculated with the following formula: (Piso/MPAP) − 1.
Calculated with the following formula: (Piso/[1.65 × MPAP − 7.79]) − 1.
Calculated with the following formula: (Piso/SRVP) − 1.
Calculated with the following formula: (Piso − MPAP)/(CMRI‐derived RVSV).
Calculated with the following formula: (Piso − MPAPcalc)/(CMRI‐derived RVSV).
Calculated with the following formula: (Piso − SRVP)/(CMRI‐derived RVSV).
Calculated by solving the equations: RVP = α(eRVV·β − 1) (n = 48).
Calculated using the following formula: Eed = α·β·eRVEDV·β (n = 48).
Figure 2Bland‒Altman plots of 13 SG‐ and Pressure‐cath‐derived indices of RVP. There were no systematic trends based on the values of the 13 indices. In all indices, the limits of agreement included 0, indicating that there were no significant differences between SG‐ and Pressure‐cath‐derived indices. dp/dt‐max, maximum dp/dt; dp/dt‐min, minimum dp/dt; Ea, arterial elastance; Eed, end‐diastolic elastance; Ees, end‐systolic elastance; HR, heart rate; MPAP, mean pulmonary arterial pressure; MPAPcalc, calculated end‐systolic pressure using MPAP; Piso, isovolumic pressure; Pressure‐cath, high‐fidelity micromanometry; RV, right ventricular; RVEDP, RV end‐diastolic pressure; RVP‐min, minimum RV pressure; SG‐cath, Swan–Ganz catheterization; SRVP, systolic RV pressure
Right ventricular pressure and indices of right ventricular function in controls and in patients with pulmonary hypertension
|
| ||||
|---|---|---|---|---|
| Swan–Ganz catheterization‐derived data | High‐fidelity micromanometry‐derived data | |||
| Controls | Patients with pulmonary hypertension | Controls | Patients with pulmonary hypertension | |
|
| 16 | 57 | 16 | 57 |
| SRVP (mmHg) | 29.1 ± 5.0 | 52.7 ± 16.6 | 25.7 ± 5.0 | 47.8 ± 16.1 |
| RVP‐min (mmHg) | 0.8 ± 2.6 | 2.7 ± 2.7 | 0.0 ± 2.2 | 1.0 ± 3.0 |
| RVEDP (mmHg) | 4.5 ± 3.0 | 7.2 ± 3.0 | 3.3 ± 2.0 | 4.8 ± 2.8 |
| Piso (mmHg) | 47.6 ± 13.8 | 73.6 ± 23.9 | 44.1 ± 8.2 | 67.0 ± 17.1 |
| Ees/Ea (MPAP) | 2.00 ± 0.86 | 1.31 ± 0.50 | 1.80 ± 0.47 | 1.13 ± 0.44 |
| Ees/Ea (MPAPcalc) | 1.68 ± 0.90 | 0.67 ± 0.40 | 1.51 ± 0.69 | 0.55 ± 0.37 |
| Ees/Ea (SRVP) | 0.64 ± 0.41 | 0.44 ± 0.36 | 0.73 ± 0.20 | 0.47 ± 0.34 |
| dp/dt‐max (mmHg/s) | 396.4 ± 87.0 | 532.4 ± 183.6 | 329.3 ± 65.4 | 454.5 ± 113.4 |
| dp/dt‐min (mmHg/s) | −292.9 ± 74.3 | −516.5 ± 138.9 | −280.5 ± 58.7 | −491.7 ± 139.3 |
| Tau (s) (Weiss) | 37.5 ± 19.2 | 45.2 ± 20.4 | 38.9 ± 11.0 | 45.4 ± 18.1 |
| Tau (s) (Logistic) | 27.7 ± 12.1 | 27.8 ± 12.8 | 37.6 ± 25.5 | 34.9 ± 9.7 |
Note: Data are shown as mean ± standard error (SE).
Abbreviations: CMRI, cardiac magnetic resonance imaging; dp/dt‐max, maximum dp/dt; dp/dt‐min, minimum dp/dt; Ea, arterial elastance; Eed, end‐diastolic elastance; Ees, end‐systolic elastance; HR, heart rate; MPAP, mean pulmonary arterial pressure; MPAPcalc, calculated end‐systolic pressure using MPAP; Piso, isovolumic pressure; RVEDP, right ventricular end‐diastolic pressure; RVEDV, right ventricular end‐diastolic volume; RVP‐min, minimum right ventricular pressure; RVSV, right ventricular stroke volume; RVV, right ventricular volume; SRVP, systolic right ventricular pressure.
Calculated using the single‐beat method.
Calculated with the following formula: (Piso/MPAP) − 1.
Calculated with the following formula: (Piso/[1.65 × MPAP − 7.79]) − 1
Calculated with the following formula: (Piso/SRVP) − 1.
Calculated with the following formula: (Piso − MPAP)/(CMRI‐derived RVSV).
Calculated with the following formula: (Piso − [1.65 × MPAP − 7.79])/(CMRI‐derived RVSV).
Calculated with the following formula: (Piso − SRVP)/(CMRI‐derived RVSV).
Calculated with the following formula: MPAP/(CMRI‐derived RVSV).
Calculated with the following formula: MPAPcalc/(CMRI‐derived RVSV).
Calculated with the following formula: SRVP/(CMRI‐derived RVSV).
Calculated by solving the equations: RVP = α (eRVV·β − 1) (n = 48 [controls, n = 10; patients with pulmonary hypertension, n = 38]).
Calculated using the following formula: Eed = α·β·eRVEDV·β (n = 48 [controls, n = 10; patients with pulmonary hypertension, n = 38]).
<0.05 versus Controls (Swan–Ganz catheterization‐derived data) by Wilcoxon's test.
0.05 versus Controls (High‐fidelity micromanometry‐derived data) by Wilcoxon's test.